Paradoxical effects of anti-TNF-α agents in inflammatory diseases

References

• Pham T, Bachelez H, Berthelot JM et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine. 78(Suppl. 1), 15–185 (2011).
   PubMed Web of Science ®Google Scholar
• Bradley JR. TNF-mediated inflammatory disease. J. Pathol. 214(2), 149–160 (2008).
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244–279 (2008).
   PubMed Web of Science ®Google Scholar
• Biton J, Boissier MC, Bessis N. TNFα: activator or inhibitor of regulatory T cells? Joint Bone Spine 79(2), 119–123 (2012).
   PubMed Web of Science ®Google Scholar
• Benucci M, Saviola G, Manfredi M et al. Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed. 83(1), 72–80 (2012).
   PubMedGoogle Scholar
• Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract. Res. Clin. Rheumatol. 25(4), 549–567 (2011).
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab inpatients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72(10), 1605–1612 (2013)
   PubMed Web of Science ®Google Scholar
• Wendling D, Balblanc JC, Briançon D et al. Onset or exacerbation of cutaneous psoriasis during TNF alpha antagonist therapy. Joint Bone Spine 75(3), 315–318 (2008).
   PubMed Web of Science ®Google Scholar
• Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 20(2), 100–108 (2009).
   PubMed Web of Science ®Google Scholar
• Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68(2), 209–215 (2009).
   PubMed Web of Science ®Google Scholar
• Tillack C, Ehmann LM, Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut (2013) (Epub ahead of print).
   Google Scholar
• Klein RQ, Spivack J, Choate KA. Psoriatic skin lesions induced by certolizumab pegol. Arch. Dermatol. 146, 1055–1056 (2010).
   PubMedGoogle Scholar
• Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59(7), 996–1001 (2008).
   PubMed Web of Science ®Google Scholar
• Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin. Arthritis Rheum. 40(3), 233–240 (2010).
   PubMed Web of Science ®Google Scholar
• Denadai R, Teixeira FV, Steinwurz F et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J. Crohns Colitis. 7(7), 517–524 (2013).
   PubMed Web of Science ®Google Scholar
• Seneschal J, Milpied B, Vergier B et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br. J. Dermatol. 161(5), 1081–1088 (2009).
   PubMed Web of Science ®Google Scholar
• Ma HL, Napierata L, Stedman N et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 62(2), 430–440 (2010).
   PubMed Web of Science ®Google Scholar
• Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin. Exp. Rheumatol. 30(5), 700–706 (2012).
   PubMed Web of Science ®Google Scholar
• Viguier M, Richette P, Bachelez H et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev. Clin. Immunol. 5(4), 421–431 (2009).
   PubMed Web of Science ®Google Scholar
• Flendrie M, Vissers WH, Creemers MC et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7(3), R666–R676 (2005).
   PubMed Web of Science ®Google Scholar
• Hernández MV, Sanmartí R, Cañete JD et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumour necrosis factor antagonists. Study based on the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. Arthritis Care Res (Hoboken) (2013) (Epub ahead of print).
   Google Scholar
• Puig L, Morales-Múnera CE, López-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 225(1), 14–17 (2012).
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul. Immunol. Inflamm. 21(1), 19–27 (2013).
   PubMed Web of Science ®Google Scholar
• Rifkin LM, Birnbaum AD, Goldstein DA. TNF Inhibition for ophthalmic indications: current status and outlook. Bio. Drugs 27(4), 347–357 (2013).
   Google Scholar
• Wendling D. Uveitis in seronegative arthritis. Curr. Rheumatol. Rep.14(5), 402–408 (2012).
   PubMed Web of Science ®Google Scholar
• Guignard S, Gossec L, Salliot C et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares inpatients with spondylarthropathy: a retrospective study. Ann. Rheum. Dis. 65(12), 1631–1634 (2006).
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52(8), 2447–2451 (2005).
   PubMed Web of Science ®Google Scholar
• Sieper J, Koenig A, Baumgartner S et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann. Rheum. Dis. 69(1), 226–229 (2010).
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Rødevand E, Holck P et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68(5), 696–701 (2009).
   PubMed Web of Science ®Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 56(10), 3248–3252 (2007).
   PubMed Web of Science ®Google Scholar
• Wendling D, Paccou J, Berthelot JM et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin. Arthritis Rheum. 41(3), 503–510 (2011).
   PubMed Web of Science ®Google Scholar
• Fouache D, Goëb V, Massy-Guillemant N et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48(7), 761–764 (2009).
   PubMed Web of Science ®Google Scholar
• Horai R, Caspi RR. Cytokines in autoimmune uveitis. J. Interferon. Cytokine Res. 31(10), 733–744 (2011).
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Giampietro C, Gaujoux T et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J. Rheumatol. 39(2), 233–239 (2012)
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 57(4), 639–647 (2007).
   PubMed Web of Science ®Google Scholar
• Toussirot É, Houvenagel É, Goëb V et al. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 79(5), 457–463 (2012).
   PubMed Web of Science ®Google Scholar
• Fernández Salazar L, Barrio Andrés J, González Hernández JM. Crohn's disease diagnosis during adalimumab treatment. Scand. J. Gastroenterol. 48(2), 254–255 (2013).
   PubMed Web of Science ®Google Scholar
• Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin. Arthritis Rheum. 39(3), 176–181 (2009).
   PubMed Web of Science ®Google Scholar
• Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn's disease. Discov. Med. 14(77), 253–262 (2012).
   PubMed Web of Science ®Google Scholar
• Maneiro JR, Salgado E, Gomez-Reino JJ et al. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin. Arthritis Rheum. 42(1), 89–103 (2012).
   PubMed Web of Science ®Google Scholar
• Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin. Exp. Rheumatol. 26(3), 471–475 (2008).
   PubMed Web of Science ®Google Scholar
• Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. Semin. Arthritis Rheum. 39(4), 313–319 (2010).
   PubMed Web of Science ®Google Scholar
• Vigne C, Tebib JG, Pacheco Y, Coury F. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine 80(1), 104–107 (2013).
   PubMed Web of Science ®Google Scholar
• Daïen CI, Monnier A, Claudepierre P et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 48(8), 883–886 (2009).
   PubMed Web of Science ®Google Scholar
• Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J. Crohns Colitis. 6(6), 708–712 (2012).
   PubMed Web of Science ®Google Scholar
• Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36(3), 159–67 (2006).
   PubMed Web of Science ®Google Scholar
• Toussirot E, Berthelot JM, Pertuiset E et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J. Rheumatol. 36(11), 2421–2427 (2009).
   PubMed Web of Science ®Google Scholar
• Deng A, Harvey V, Sina B et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch. Dermatol. 142(2), 198–202 (2006).
   PubMedGoogle Scholar
• Wendling D, Biver-Dalle C, Vidon C et al. Lichen planus under anti TNF therapy for ankylosing spondylitis. Joint Bone Spine 80(2), 227–228 (2013).
   PubMed Web of Science ®Google Scholar
• Wendling D, Streit G, Lehuédé G et al. Cutaneous lymphocytic vasculitis during TNF-alpha antagonist therapy for polyarthritis. Joint Bone Spine 73(2), 215–216 (2006).
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J. Rheumatol. 31(10), 1955–1958 (2004).
   PubMed Web of Science ®Google Scholar
• Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73(6), 710–713 (2006).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4), 242–251 (2007).
   PubMed Web of Science ®Google Scholar
• Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin. Proc. 87(8), 739–745 (2012).
   Google Scholar
• Wendling D. Biologics in the treatment of primary inflammatory myositis. Joint Bone Spine 74(4), 316–318 (2007).
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Yukawa N, Ohmura K et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin. Rheumatol. 29(5), 563–566 (2010).
   PubMed Web of Science ®Google Scholar
• Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun. Rev. 13(1), 15–19 (2013).
   PubMed Web of Science ®Google Scholar
• Agarwal A, Andrews JM. Systematic review: IBD-associated pyodermagangrenosum in the biologic era, the response to therapy. Aliment Pharmacol. Ther. 38(6), 563–572 (2013)
   PubMed Web of Science ®Google Scholar
• Jaimes-López N, Molina V, Arroyave JE et al. Development of pyodermagangrenosum during therapy with infliximab. J. Dermatol. Case Rep. 3(2), 20–23 (2009)
   PubMedGoogle Scholar
• Vandevyvere K, Luyten FP, Verschueren P et al. Pyodermagangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin. Rheumatol. 26(12), 2205–2206 (2007)
   PubMed Web of Science ®Google Scholar
• Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. J. Crohns Colitis. 7(4), 257–262 (2013).
   PubMed Web of Science ®Google Scholar
• Wendling D, Dougados M, Berenbaum F et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J. Rheumatol. 39(12), 2327–2331 (2012).
   PubMed Web of Science ®Google Scholar
• Wendling D, Letho-Gyselinck H, Guillot X, Prati C. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J. Rheumatol. 39(3), 657 (2012).
   PubMed Web of Science ®Google Scholar
• Wendling D, Dernis E, Prati C et al. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J. Rheumatol. 38(10), 2284 (2011).
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr. Opin. Rheumatol. 25(1), 56–64 (2013).
   PubMed Web of Science ®Google Scholar